Studienliste - Universitätsklinik für Medizinische Onkologie und Universitätsklinik für Radio-Onkologie - Inselspital Kontakt

61 Aktive Studien der Universitätsklinik für Medizinische Onkologie und Universitätsklinik für Radio-Onkologie

FACHGEBIETE

andere

Ordner-Nr. 181/11

  • The radiation metabolic signature of patients undergoing radiotherapy. A Pilot Study
 Studienleiter:Fr. Dr. Kristina Lössl
 Study-Nurse:Frau Brigitte Dorn
 Back-up:Herr Timo Nannen


Status: aktiv seit 17.01.2014

 

Ordner-Nr. 092/14

  • SAKK 96/12: Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial
 Studienleiter:Dr. med. Julian Schardt
 Study-Nurse:Frau Olivia Aerni
 Back-up:Frau Farzaneh Borner


Status: aktiv seit 17.11.2014

 

Ordner-Nr.

  • SENS: A structured early palliative care intervention for patients with advanced cancer – a randomized controlled trial with a nested qualitative study SENSTrial)

    Kurzprotokoll
 Studienleiter:Prof. Dr. med. Steffen Eychmüller
 Co-Investigator:Frau Monica Fliedner
 Study-Nurse:Frau Renata Bünter


Status: aktiv seit 01.12.2013

 

Ordner-Nr.

  • PALL-DEC: Clinical decision-making in palliative situations: The role and prerequisites of patients’ mental representation.
 Studienleiter:Prof. Dr. Jürg Bernhard
 Co-Investigator:Fr. Dr. med. Manuela Rabaglio


Status: aktiv seit 20.10.2014

 

Ordner-Nr. 2016-00520

  • Genetic characterization and enumeration of single, circulating tumour cells isolated from blood of renal cell carcinoma patients.
 Studienleiter:Dr. med. Julian Schardt
Hinweis: Studie wird nicht durch die KFE der UKMO betreut.


Status: aktiv seit 16.06.2016

 

Ordner-Nr. 2016-00008

  • DOSIS Studie: Dose-intensified Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastases (DOSIS) versus Conventional Radiation Therapy: a Phase II Randomized Controlled Trial.
 Studienleiter:Fr. Dr. med. Evelyn Herrmann


Status: aktiv seit 16.08.2017

 

Ordner-Nr. 2016-00602

  • PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
 Studienleiter:Prof. Dr. Carlo Largiader
 Co-Investigator:Prof. Dr. Daniel Aebersold
 Study-Nurse:Dr. med. Marc Wehrli


Status: aktiv seit 07.09.2017

 

Ordner-Nr. 2016-01487

  • EORTC_31102_TIGER_1407-GUCG: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED BY HIGH-DOSE CARBOPLATIN AND ETOPOSIDE (TI-CE) AS FIRST SALVAGE TREATMENT IN RELAPSED OR REFRACTORY GERM CELL TUMORS
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Antje Kramer


Status: aktiv seit 21.12.2017

 

Ordner-Nr. 2018-01756

  • LuCimiR : Circulating microRNA as biomarkers in lung squamous cell carcinoma. microRNA.
 Studienleiter:Dr. med. Simon Häfliger


Status: aktiv seit 26.11.2018

 
zurück nach oben

Blase

Ordner-Nr. 2017-01240

  • NITIMIB-Trial: Neoadjuvant Immunotherapy with Durvalumab in Combination with Tremelimumab in Patients with Muscle-invasive Bladder cancer ineligible for Cisplatin-based Chemotherapy. A Single center, Open-label, Phase II trial."
 Studienleiter:Dr. med. Julian Schardt
 Study-Nurse:Frau Silvia Andrist
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.06.2018

 
zurück nach oben

Hirn

Ordner-Nr.

  • RESURGE: Randomized controlled comperative phase II trial on surgery for glioblastoma recurrence

    Kurzprotokoll
 Studienleiter:PD Dr. med. Philippe Schucht
 Co-Investigator:Prof. Dr. Adrian Ochsenbein
 Study-Nurse:Frau Karin Lussi
Hinweis: Diese Studie wird durch die Neurochirurgie durchgeführt.


Status: aktiv seit 18.05.2015

 

Ordner-Nr.

  • IOSI-RTO-001: Stereotactic Radiosurgery or Hypofractionated Image-Guided Radiotherapy to the surgical cavity after resection of brain metastases: a multicenter, single arm, open-label, phase II trial
 Studienleiter:Fr. Dr. med. Evelyn Herrmann
 Study-Nurse:Frau Brigitte Dorn
 Back-up:Herr Timo Nannen


Status: aktiv seit 04.09.2018

 

Ordner-Nr. 2016-00707

  • SAKK 67/15 BASILEA (CDI-CS-003): An open-label Phase 1/2a study of BALI 01553 administered as intravenous 48-hour infusions in adult patients with advanced solid tumors or recurrent glioblastoma.
 Studienleiter:Fr. Dr. med. Nurgül Usluoglu
 Co-Investigator:Dr. med. Simon Häfliger
 Study-Nurse:Frau Sandrina Hohl


Status: aktiv seit 19.11.2018

 
zurück nach oben

Hoden

  • zur Zeit keine aktive Studie
zurück nach oben

Kolorektal

Ordner-Nr. 2017-0015

  • Amgen 20140299: A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
 Studienleiter:Dr. med. Martin Berger
 Co-Investigator:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Antje Kramer


Status: aktiv seit 10.04.2019

 

Ordner-Nr. 2016-00550

  • SAKK 41/13 - Aspirin: Adjuvant aspirin Treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, palcebo-controlled, phase III trial.
 Studienleiter:Dr. med. Martin Berger
 Study-Nurse:Frau Nicole Corballis


Status: aktiv seit 08.01.2018

 

Ordner-Nr. 2016-01778

  • SAKK 41/16 (RECAP): Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal cancer. A multicenter phase Ib trial (RECAP).
 Studienleiter:Dr. med. Martin Berger
 Study-Nurse:Frau Antje Kramer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 02.10.2018

 
zurück nach oben

Kopf/Hals

Ordner-Nr. 2016-00733

  • UP-FRONT NECK Trial: Definitive (chemo)-radiotherapy with or without up-front neck dissection for regionally advanced Head and Neck Squamous Cell Carcinoma - A phase III multi-center prospective randomized controlled trial with two additional observational cohort”
 Studienleiter:Dr. med. Olgun Elicin
 Study-Nurse:Fr. Sandra Fuchser
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.12.2016

 
zurück nach oben

Leber/Gallengang

  • zur Zeit keine aktive Studie
zurück nach oben

Leukämien

Ordner-Nr. 256/14

  • HOVON 103 AML / SAKK 30/10 Selinexor: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged  66 years .
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Anke Klingenberg-Rettich
 Back-up:Frau Christine Tromp
Hinweis: As announced in November, the inclusion of the HOVON 103 AML study would be put on hold when 100 evaluable patients were randomized. Today the last patient has been registered and randomized. As of now, no new patients can be informed about the study and/or included until the interim analysis has been performed. When the interim analysis shows that the study can be continued, inclusion of patients will be resumed. Meldung vom 28.12.2018


Status: aktiv seit 10.08.2017

 

Ordner-Nr. 346/15 (PB_2016-0054

  • GRAALL-2014 + GRAAPH-2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years). Comprising 3 sub-studies according to lineage GRAALL-2014/B Ph-negative B-lineage ALL GRAALL-2014/T T-ALL GRAAPH-2014 Ph+ ALL
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Anke Klingenberg-Rettich
 Back-up:Frau Doris Jäggi-Meinken


Status: aktiv seit 22.02.2017

 

Ordner-Nr.

  • CLL 13: EINE PROSPEKTIVE, UNVERBLINDETE, MULTIZENTRISCHE PHASE-III-STUDIE ZUM VERGLEICH VON VIER KOMBINATIONSTHERAPIEN BEI PATIENTEN MIT UNBEHANDELTER CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL) OHNE DEL(17P) ODER TP53 MUTATION: STANDARDCHEMOIMMUNTHERAPIE (FCR/BR), RITUXIMAB UND VENETOCLAX (RVE), OBINUTUZUMAB (GA101) UND VENETOCLAX (GVE) SOWIE OBINUTUZUMAB, IBRUTINIB UND VENETOCLAX (GIVE)
 Studienleiter:Dr. med. Andres Martin
 Co-Investigator:Dr. med. Urban Novak
 Study-Nurse:Frau Karin Pagalies
 Back-up:Frau Bettina Cliffe


Status: aktiv seit 18.09.2017

 

Ordner-Nr. 2018-00606

  • Novartis CPKC412E2301: A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) or chemotherapy plus placebo in newly diagnosed patients with FLT-3 mutation negative acute myeloid leukemia (AML)
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Christine Tromp
 Back-up:Frau Ursula Riesen


Status: aktiv seit 13.11.2018

 
zurück nach oben

Lunge (NSCLC)

Ordner-Nr. 249/15 (PB_2016-0030

  • MK-3475-091_EORTC 1416-LCG (PEARLS): A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS).

    Kurzprotokoll
 Studienleiter:Fr. Dr. med. Amina Scherz
 Co-Investigator:Prof. Dr. Adrian Ochsenbein
 Study-Nurse:Frau Sandrina Hohl
 Back-up:Frau Olivia Aerni


Status: aktiv seit 28.07.2016

 

Ordner-Nr. 2018-01254

  • SAKK 19/17: First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II. trial.
 Studienleiter:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Sandrina Hohl


Status: aktiv seit 13.12.2018

 

Ordner-Nr.

  • SAKK 19/18: Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer (SQCLC) overexpressing FGFR mRNA. A multicenter, single arm phase II trial
 Studienleiter:Dr. med. Simon Häfliger
 Study-Nurse:Frau Sandrina Hohl


Status: aktiv seit 00.00.0000

 
zurück nach oben

Lunge (SCLC)

  • zur Zeit keine aktive Studie
zurück nach oben

Lymphome: Diverse

Ordner-Nr. 176/13

  • IELSG 37: Assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens, newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL). Phase III

    Kurzprotokoll
 Studienleiter:Fr. Dr. Codruta Ionescu
 Study-Nurse:Frau Brigitte Dorn
 Back-up:Herr Timo Nannen


Status: aktiv seit 23.01.2014

 

Ordner-Nr. 055/15

  • SAKK 36/13: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase II trial

    Kurzprotokoll
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Bettina Cliffe


Status: aktiv seit 28.11.2016

 

Ordner-Nr. 194/15

  • SAKK 35/14: Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial

    Externer Link
    Kurzprotokoll
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Bettina Cliffe


Status: aktiv seit 09.11.2015

 

Ordner-Nr. 2016-01351

  • BAL-trial: Brentuximab Vedotin and BeEAM high-dose chemotherapy (B-BeEAM) with autologous stem cell transplantation for CD30+ lymphomas, a phase I/II study (the BAL-trial).
 Studienleiter:Prof. Dr. Thomas Pabst
 Co-Investigator:Dr. med. Urban Novak
 Study-Nurse:Frau Sandrina Hohl
 Back-up:Frau Doris Jäggi-Meinken


Status: aktiv seit 03.09.2018

 

Ordner-Nr. 2016-01917

  • 4SC-201-6-2015: A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Anke Klingenberg-Rettich
 Back-up:Frau Christine Tromp


Status: aktiv seit 01.02.2018

 

Ordner-Nr. 3380

  • Amgen Protocol Number (Capilano) 20150291: A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation
 Studienleiter:Frau Dr. med. Barbara Jeker
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Karin Pagalies
 Back-up:Frau Ursula Riesen


Status: aktiv seit 08.03.2018

 

Ordner-Nr. 3473

  • HOVON 127 / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Anke Klingenberg-Rettich


Status: aktiv seit 07.05.2018

 

Ordner-Nr. 2017-01223

  • PAMAL trial: Pedometer-based activity monitoring after autologous transplantation in lymphoma and myeloma patients.
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Irene Briner


Status: aktiv seit 20.11.2017

 

Ordner-Nr. 3549

  • TRIANGLE (SAKK): Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing induction in generalized mantle cell Lymphoma - a randomized european mcl network trial.
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Christine Tromp
 Back-up:Frau Yaël Balderer


Status: aktiv seit 13.03.2018

 

Ordner-Nr. 2018-00162

  • Amgen 20150136: An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Monika-Krista Zackel
 Back-up:Frau Doris Jäggi-Meinken


Status: aktiv seit 11.07.2018

 

Ordner-Nr. 2018-00828

  • Symptom prevalence and health related quality of life in patients with lymphoma undergoing high-dosage chemotherapy and autologous stem cell transplantation – a longitudinal observation study


Status: aktiv seit 06.07.2018

 
zurück nach oben

Lymphome: Hodgkin

Ordner-Nr. 2016-02186

  • HD 21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Bettina Cliffe
 Back-up:Frau Karin Pagalies


Status: aktiv seit 07.07.2017

 
zurück nach oben

Lymphome: Multiples Myelom

Ordner-Nr. 2016-00442

  • BEB-2 Trial: A randomized phase II trial comparing Bendamustine and Melphalan with Melphalan alone as conditioning regimen for autologous stem cell transplantation (ASCT) in myeloma patients (BEB-2 trial).
 Studienleiter:Prof. Dr. Thomas Pabst
 Co-Investigator:Fr. Dr. med. Sarah Farag
 Study-Nurse:Frau Anke Klingenberg-Rettich


Status: aktiv seit 20.07.2017

 

Ordner-Nr. 2018-00615

  • MOCCCA-trial: A randomized phase II trial comparing stem cell mobilization with hemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients.
 Studienleiter:Frau Dr. med. Barbara Jeker
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Monika-Krista Zackel
 Back-up:Frau Anke Klingenberg-Rettich


Status: aktiv seit 20.09.2018

 

Ordner-Nr. 2018-00820

  • SAKK 39/16 OptiPOM : Alternate day dosing of Pomalidomide in patients with refractory Multiple Myeloma. A multicenter, single arm, open label phase II trial
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Anke Klingenberg-Rettich


Status: aktiv seit 19.11.2018

 

Ordner-Nr. 2017-01223

  • PAMAL Trial: Pedometer-based activity monitoring after autologous transplantation in lymphoma and myeloma patients.
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Irene Briner


Status: aktiv seit 21.11.2017

 
zurück nach oben

Magen

  • zur Zeit keine aktive Studie
zurück nach oben

Mamma

Ordner-Nr. 018/2015

  • IBCSG 48-14 POSITIVE: A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Olivia Aerni
 Back-up:Frau Farzaneh Borner


Status: aktiv seit 30.05.2016

 
zurück nach oben
"Prevention (Postmenopausal)"
  • zur Zeit keine aktive Studie
zurück nach oben
"Early"

Ordner-Nr. 271/14

  • IBCSG 50-14 / BIG 14-02 OLYMPIA: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

    Kurzprotokoll
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Farzaneh Borner
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.09.2017

 

Ordner-Nr.

  • CAPRICE study: Importance of exercise training therapy timing with regard to cardiotoxicity and patient preference in early breast cancer patients undergoing adjuvant chemo-therapy
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
Hinweis: Die Studie wird in Zusammenarbeit mit der Prof. Dr. med. M. Wilhelm, Präventive Kardiologie und Sportmedizin durchgeführt.


Status: aktiv seit 16.05.2019

 

Ordner-Nr. 2018-00536

  • ALEXANDRA / IMpassion 030 / BIG 16-05/AFT-27/WO39391: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTIPD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Olivia Aerni


Status: aktiv seit 16.05.2019

 
zurück nach oben
"Lokalrezidiv"
  • zur Zeit keine aktive Studie
zurück nach oben
"Advanced"

Ordner-Nr. 2016-01006

  • SAKK 24/14: Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer - A multicenter single arm phase II Trial.
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Olivia Aerni


Status: aktiv seit 15.04.2017

 

Ordner-Nr. 2017-0015

  • Amgen 20140299: A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
 Studienleiter:Dr. med. Martin Berger
 Co-Investigator:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Antje Kramer


Status: aktiv seit 10.04.2019

 
zurück nach oben
"Male"
  • zur Zeit keine aktive Studie
zurück nach oben

Melanom

  • zur Zeit keine aktive Studie
zurück nach oben

Mesotheliom

  • zur Zeit keine aktive Studie
zurück nach oben

Neuroendokrine Tumoren

Ordner-Nr. 2017-00466

  • COMPETE: A prospective, randomised, Controlled, Open-Label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 1 77Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptorpositive (SSTR+) , neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). COMPETE. ITM - LET - 01.
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Antje Kramer


Status: aktiv seit 27.12.2017

 
zurück nach oben

Oesophagus

  • zur Zeit keine aktive Studie
zurück nach oben

Ovar, Cervix, Endometrium

Ordner-Nr. 2017-02024

  • C-145-04: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Farzaneh Borner
 Back-up:Frau Olivia Aerni


Status: aktiv seit 20.12.2018

 

Ordner-Nr. 2018-01772

  • AtTEnd Trial (SAKK): PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL OF ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Farzaneh Borner


Status: aktiv seit 02.05.2019

 
zurück nach oben

Pankreas

  • zur Zeit keine aktive Studie
zurück nach oben

Prostata

Ordner-Nr. 101/09

  • STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. A 5-stage 6-arm randomized controlled trial

    Externer Link
 Studienleiter:PD Dr. George Thalmann
Hinweis: Randomizations to arm G is stopped. Arms A and H (newly-diagnosed M1 patients)are still open. Meldung vom 17. Jan. 2014


Status: aktiv seit 10.10.2013

 

Ordner-Nr. 306/2014

  • SAKK 63/12: Prospective cohort study with collection of clinical data and serum of patients with prostate disease
 Studienleiter:Prof. Dr. Daniel Aebersold
 Study-Nurse:Fr. Sandra Fuchser
 Back-up:Frau Ulla Schüpbach


Status: aktiv seit 17.02.2015

 

Ordner-Nr. 2017-00842

  • EORTC Radiation Oncology Group EORTC Genito-Urinary Cancers Group (EORTC 1414-RO: Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG (Pegasus)
 Studienleiter:Prof. Dr. Daniel Aebersold
 Study-Nurse:Frau Ulla Schüpbach


Status: aktiv seit 29.01.2018

 

Ordner-Nr. 2017-00584

  • SAKK 08/15 PROMET: Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients with Prostate Cancer after Prostatectomy
 Studienleiter:Prof. Dr. Daniel Aebersold
 Study-Nurse:Frau Ulla Schüpbach


Status: aktiv seit 06.10.2017

 

Ordner-Nr. 2018-00164

  • STORM: Salvage treatment of oligo recurrent nodal prostate cancer metastases. To compare metastases-free survival between metastasis-directed therapy and metastasis-directed therapy with whole pelvis RT
 Studienleiter:Dr.med. Mohamed Shelan
 Study-Nurse:Fr. Sandra Fuchser
 Back-up:Herr Timo Nannen


Status: aktiv seit 24.01.2019

 
zurück nach oben

Sarkome

Ordner-Nr. 2017-01449

  • EORTC ANITA: A Phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosporine-based first line chemotherapy for inoperable disease "ANITA"
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Nicole Corballis
 Back-up:Frau Antje Kramer


Status: aktiv seit 02.10.2018

 

Ordner-Nr. 2017-01063

  • E-trab: GERIATRIC ASSESSMENT OF ELDERLY “UNSUITED” PATIENTS RECEIVING TRABECTEDIN IN FIRST LINE TREATMENT FOR ADVANCED SOFT TISSUE SARCOMAS (STS)
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Antje Kramer


Status: aktiv seit 25.10.2017

 

Ordner-Nr. 3787

  • SAKK 57/16 : NAPAGE: NAb-PAclitaxel and GEmcitabine in advanced soft tissue sarcoma. A multicenter open-label single arm phase Ib/IIa trial
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Nicole Corballis
Hinweis: We are happy to inform you that the Phase I of the SAKK 57/16 trial has been successfully completed with 6 enrolled patients and without any DLT observed. After safety evaluation of the available patients’ data, the extended trial team has concluded that the Recommended Phase 2 Dose (RP2D) is Dose Level 1 according to protocol (150 mg/m2 nab-paclitaxel and 1000 mg/m2 gemcitabine given on day 1 and day 15 of every 28-day cycle). With this, phase II of the SAKK 57/16 trial is officially open as of today using Dose Level 1. Meldung der SAKK vom 10.04.2019


Status: aktiv seit 01.11.2018

 
zurück nach oben

Solide Tumoren

Ordner-Nr.

  • SAKK 65/16: TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.
 Studienleiter:Dr. med. Simon Häfliger
 Co-Investigator:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Antje Kramer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 18.03.2019

 
zurück nach oben

Supportivtherapie

  • zur Zeit keine aktive Studie
zurück nach oben

Urothelkarzinom/Nierenzellkarzinom

Ordner-Nr. 2017DR3115

  • E7080-G000-307: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).
 Studienleiter:Dr. med. Julian Schardt
 Study-Nurse:Frau Antje Kramer
 Back-up:Frau Silvia Andrist
Hinweis: We would like to inform you that entry into Screening for the CLEAR Study (E7080-G000-307) is estimated to close around mid June 2019, in order to reach the target of 1050 subjects randomized. There are currently 961 subjects randomized and 27 ongoing in screening in the study as of 07 May 2019. If you are considering potential patients for recruitment to the study, please arrange to start the screening period and register the patient in screening in the IRT system (IWRS) by 12 June 2019. Mitteilung vom 8. Mai 2019


Status: aktiv seit 10.10.2018

 

Ordner-Nr. 2018-00176

  • SAKK 06/17 : Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II trial
 Studienleiter:PD Dr.med. Roland Seiler
 Co-Investigator:Dr. med. Julian Schardt
 Study-Nurse:Frau Silvia Andrist
Hinweis: Studie wird in Zusammenarbeit mit der Urologie durchgeführt.


Status: aktiv seit 13.08.2018

 

Ordner-Nr.

  • BAYER 1163877/ 17403 Studie: A randomized, open label, multicenter, seamless Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy
 Studienleiter:PD Dr.med. Beat Roth
 Co-Investigator:Dr. med. Julian Schardt
 Study-Nurse:Frau Silvia Andrist
 Back-up:Frau Antje Kramer


Status: aktiv seit 31.01.2019

 
zurück nach oben